FDA Adverse Event Injury Summary report: N

WATCHMAN LAA CLOSURE DEVICE & DELIVERY SYSTEM

MDR report key: 13051695 · Received December 21, 2021

Report

Report Number
2134265-2021-16031
Event Type
Injury
Date Received
December 21, 2021
Date of Event
December 14, 2017
Report Date
December 21, 2021
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NGV
UDI-DI
08714729838234
PMA / PMN Number
P130013
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Description of Event or Problem · 0

ASAP TOO STUDY. IT WAS REPORTED THAT THROMBOSIS OCCURRED. A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS BEING PERFORMED. PRIOR TO THE INDEX PROCEDURE, ASPIRIN WAS ADMINISTERED AND AFTER THE IMPLANT PROCEDURE THE PATIENT WAS STARTED ON CLOPIDOGREL, ASPIRIN WAS CONTINUED. THE PATIENT UNDERWENT SUCCESSFUL PLACEMENT OF A 24 MM WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE WITH COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 17 MM. ONE DAY POST INDEX PROCEDURE, THE PATIENT WAS DISCHARGED. ON (B)(6) 2017, 85 DAYS POST INDEX PROCEDURE AT THE 3 MONTH FOLLOW-UP VISIT, TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE) REVEALED A THROMBUS ON THE ATRIAL FACING SURFACE OF THE DEVICE. OF NOTE, DURING 3-MONTH CORE LAB TEE FOLLOW-UP VISIT THE THROMBUS WAS NOTED, HOWEVER, PER SITE NO THROMBUS WAS NOTED. THE SIZE OF THE MAXIMUM AREA OF DEVICE THROMBUS 0.42 CM2 AND THE THROMBUS WAS NON MOBILE. DURING THIS TIME, THE PATIENT WAS ON ASPIRIN AND CLOPIDOGREL. ON (B)(6) 2018, DURING THE 12 MONTH FOLLOW-UP VISIT NO THROMBUS WAS NOTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1953040 WATCHMAN LAA CLOSURE DEVICE & DELIVERY SYSTEM SYSTEM, APPENDAGE CLOSURE, LEFT ATRIAL NGV BOSTON SCIENTIFIC CORPORATION 10371 0020270378 08714729838234

Patients

Seq Age Sex Outcome Treatment
1 76 YR Male Other